Natalizumab 300mg/15ml solution for infusion vials
NHS hospitals in England used £28,902,010 of indicative cost of Natalizumab 300mg/15ml solution for infusion vials in the 12 months to July 2026, about 0.1% of all hospital medicines spend. That is down 20.6% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Natalizumab 300mg/15ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Natalizumab 300mg/15ml solution for infusion vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Imperial College Healthcare Nhs Trust | £6,227,430 |
| University Hpls North Midlands Nhs Trust | £1,770,710 |
| Salford Royal Nhs Foundation Trust | £1,247,520 |
| University Hospital Southampton Nhs Ft | £1,100,620 |
| Barts Health Nhs Trust | £1,099,490 |
| Southend Univ Hosp Nhs Foundation Trust | £1,006,830 |
| United Lincolnshire Hospitals Nhs Trust | £986,490 |
| King's College Hpl Nhs Foundation Trust | £915,300 |
| Univ Hpl B/Ham Nhs Foundation Trust | £897,220 |
| University Hpls Coventry & Warwick Trust | £884,790 |
The primary-care picture
Natalizumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Natalizumab medicine page.